Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk

Dow Jones

Feb 06, 2025

0932 ET - Eli Lilly is slightly higher is early trading after another blowout quarter driven by GLP-1 drugs. 4Q revenue rises 45% to $13.53 billion. Revenue from new products climbs by $3.15 billion to $5.64 billion, driven Zepbound and Mounjaro. Lilly's fortunes echo those of Danish rival Novo Nordisk, which sold$4.71 billion of its Ozempic drug in 4Q. Lilly shares have more than quintupled in the last five years. Rival drug makers, such as Novartis, have admitted hunting for obesity drugs of their own. Lilly and Novo have major first-mover advantage, with smaller players such as Viking Therapeutics still playing catchup. Anya Schiess, a partner at JPMorgan's asset management unit, is among those who have predicted GLP-1s will be the best-selling class of drugs yet. (rob.curran@dowjones.com)

(END) Dow Jones Newswires

February 06, 2025 09:32 ET (14:32 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2509274460"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2509274460\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2509274460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-06 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509274460","market":"other","top_or_hot":-1,"title":"Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0932 ET - Eli Lilly is slightly higher is early trading after another blowout quarter driven by GLP-1 drugs. 4Q revenue rises 45% to $13.53 billion. Revenue from new products climbs by $3.15 billion to $5.64 billion, driven Zepbound and Mounjaro. Lilly's fortunes echo those of Danish rival Novo Nordisk, which sold$4.71 billion of its Ozempic drug in 4Q. Lilly shares have more than quintupled in the last five years. Rival drug makers, such as Novartis, have admitted hunting for obesity drugs of their own. Lilly and Novo have major first-mover advantage, with smaller players such as Viking <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> still playing catchup. Anya Schiess, a partner at JPMorgan's asset management unit, is among those who have predicted GLP-1s will be the best-selling class of drugs yet. (rob.curran@dowjones.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 06, 2025 09:32 ET (14:32 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLilly's Weight-Loss Drug Bonanza Continues -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-06 22:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0932 ET - Eli Lilly is slightly higher is early trading after another blowout quarter driven by GLP-1 drugs. 4Q revenue rises 45% to $13.53 billion. Revenue from new products climbs by $3.15 billion to $5.64 billion, driven Zepbound and Mounjaro. Lilly's fortunes echo those of Danish rival Novo Nordisk, which sold$4.71 billion of its Ozempic drug in 4Q. Lilly shares have more than quintupled in the last five years. Rival drug makers, such as Novartis, have admitted hunting for obesity drugs of their own. Lilly and Novo have major first-mover advantage, with smaller players such as Viking <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> still playing catchup. Anya Schiess, a partner at JPMorgan's asset management unit, is among those who have predicted GLP-1s will be the best-selling class of drugs yet. (rob.curran@dowjones.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 06, 2025 09:32 ET (14:32 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2089984988.USD","symbol_name":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2509274460","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509274460","pubTimestamp":1738852320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0932 ET - Eli Lilly is slightly higher is early trading after another blowout quarter driven by GLP-1 drugs. 4Q revenue rises 45% to $13.53 billion. Revenue from new products climbs by $3.15 billion to $5.64 billion, driven Zepbound and Mounjaro. Lilly's fortunes echo those of Danish rival Novo Nordisk, which sold$4.71 billion of its Ozempic drug in 4Q. Lilly shares have more than quintupled in the last five years. Rival drug makers, such as Novartis, have admitted hunting for obesity drugs of their own. Lilly and Novo have major first-mover advantage, with smaller players such as Viking Therapeutics still playing catchup. Anya Schiess, a partner at JPMorgan's asset management unit, is among those who have predicted GLP-1s will be the best-selling class of drugs yet. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1548497426.USD":"安联环球人工智能AT Acc","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0122379950.USD":"贝莱德世界健康科学A2","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LLY":"礼来","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0238689110.USD":"贝莱德环球动力股票基金"},"translate_title":"礼来公司的减肥药财富仍在继续——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":0.9},"content_text":"0932 ET - Eli Lilly is slightly higher is early trading after another blowout quarter driven by GLP-1 drugs. 4Q revenue rises 45% to $13.53 billion. Revenue from new products climbs by $3.15 billion to $5.64 billion, driven Zepbound and Mounjaro. Lilly's fortunes echo those of Danish rival Novo Nordisk, which sold$4.71 billion of its Ozempic drug in 4Q. Lilly shares have more than quintupled in the last five years. Rival drug makers, such as Novartis, have admitted hunting for obesity drugs of their own. Lilly and Novo have major first-mover advantage, with smaller players such as Viking Therapeutics still playing catchup. Anya Schiess, a partner at JPMorgan's asset management unit, is among those who have predicted GLP-1s will be the best-selling class of drugs yet. (rob.curran@dowjones.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  February 06, 2025 09:32 ET (14:32 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}